Stock Analiz

Zentalis Pharmaceuticals, Inc. ZNTL

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$1.70Market cap $167M
Open the interactive analysis →

Zentalis Pharmaceuticals, Inc. (ZNTL) is a healthcare company listed in the US with a market value of about $167M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -50%.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 36% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-80.1%
Shareholder yield6.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-246.0%
ROIC (5-yr avg.)-49.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue$0$67M$0$0———
Net income-$137M-$166M-$292M-$237M-$159M-$118M-$46M
Free cash flow-$125M-$171M-$208M-$166M-$160M-$88M-$39M
EPS (diluted)$-1.91$-2.33$-4.47$-4.48$-3.72$-4.19$-8.16
Net margin—-246.0%—————
ROIC-47.2%-39.8%-61.9%-47.1%-52.7%-28.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Zentalis Pharmaceuticals pay a dividend?

Not currently.

Is Zentalis Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Zentalis Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.